Fierce JPM Week - Virtual Agenda has ended

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Panel Discussion [clear filter]
Tuesday, January 18

9:30am EST

New paths to trial diversity
To get drug development done through COVID-19 lockdowns and social distancing, trial sponsors turned to new technology—from data management to patient monitoring—and decentralized procedures. Those same methods could potentially help biopharma bring real diversity to future clinical trials. But hurdles to these patient-centric trials still remain. How can drugmakers clear those obstacles and tap technology to make their trials look like the patient populations who’ll use the treatments being tested? 

avatar for Annalee Armstrong

Annalee Armstrong

Senior Editor, Fierce Biotech
Annalee Armstrong is a senior editor for Fierce Biotech. Prior to joining Fierce in April 2021, Annalee was an associate editor for S&P Global Market Intelligence’s healthcare news team. Before that, she was the EPA reporter covering climate and energy policy on the Hill in Washington... Read More →

avatar for Jessica L. Mega, M.D.

Jessica L. Mega, M.D.

Co-Founder and Chief Medical and Scientific Officer, Verily
Jessica L. Mega, MD, MPH, is the Co-Founder and Chief Medical and Scientific Officer at Verily. As CMSO, Dr. Mega's focus is on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes and healthcare. She oversees all... Read More →
avatar for Keiki Oishi

Keiki Oishi

President and COO, CMIC Group
Ms. Oishi is the President and COO of CMIC HOLDINGS Co., Ltd., responsible for group-wide business execution.Ms. Oishi received her Master of Science degree from the University of Tokyo. She started her career at Nikkei McGraw-Hill, Inc. in Japan (now renamed Nikkei Business Publications... Read More →
avatar for Gaelan Ritter

Gaelan Ritter

Head of Analytics Innovation and Digital Health, Bristol-Myers Squibb
As the head of Analytics Innovation and Digital Health, Gaelan and his team are responsible for leading cutting edge real-world data alliances and most importantly creating and developing innovations across R&D. He co-leads the BMS digital innovation pillar for global drug development... Read More →
avatar for Gregory Rotz

Gregory Rotz

Principal, PwC US
Greg Rotz is a Principal with PwC and leads the transformation consulting practice focused on Pharmaceuticals and Life Sciences (PLS). He brings nearly 25 years of experience shaping and serving the C-suite agenda for his clients.In his sector leadership role, Greg’s focus is to... Read More →
avatar for Ramona Sequeira

Ramona Sequeira

President, U.S. Business Unit and Global Portfolio Commercialization, Takeda Pharmaceuticals
Ramona Sequeira is President of Takeda’s US Business Unit and Global Portfolio Commercialization. She serves as a member of Takeda’s global Executive Team.Ramona joined Takeda in 2015. Through her work with Takeda and, prior to that, with Eli Lilly and Company, she has more than... Read More →
avatar for Craig Tendler, M.D.

Craig Tendler, M.D.

Global Head, Late-Stage Clinical Development, Diagnostics & Medical Affairs, Hematology & Oncology, Janssen
Craig Tendler, M.D. is Vice President, Oncology Clinical Development and Global Medical Affairs at Janssen Research & Development, LLC. In this position, he is responsible for creating robust development plans and data generation activities for all therapies in the oncology portfolio... Read More →

Tuesday January 18, 2022 9:30am - 10:30am EST

1:00pm EST

The post-COVID supply chain
While drug supply chains generally held up during the pandemic, it was no easy feat. COVID-19 taught the industry just how vulnerable the far-flung supply chain could become, and it spawned new efforts to regionalize manufacturing and double down on automation. We’ll discuss how companies adapted to the challenges and what lessons they’ll take forward to ensure secure supply chains for the long haul.

avatar for Kevin Dunleavy

Kevin Dunleavy

Staff Writer, Fierce Pharma
Kevin Dunleavy is a staff writer for Fierce Pharma. He joined the Fierce team after working 26 years as a newspaper sportswriter. He compiles Fierce Pharma’s COVID Tracker and writes about manufacturing and other topics. Kevin is a longtime resident of Northern Virginia and a graduate... Read More →

avatar for Al Boyle

Al Boyle

Chief Technical Operations and Quality Officer, Alnylam Pharmaceuticals
Al is the Chief Technical Operations and Quality Officer for Alnylam Pharmaceuticals. He leads a global organization responsible for all aspects siRNA process and analytical development, clinical and commercial manufacturing, supply chain operations, engineering, facilities and real... Read More →
avatar for Som Chattopadhyay

Som Chattopadhyay

Vice President, Global Supply Chain, Amgen
Som Chattopadhyay serves as Vice President, Global Supply Chain Organization. Reporting to Executive Vice-President of Operations, primary responsibilities include supply of medicines to patients in a safe, compliant, and efficient manner. Activities covered included network optimization... Read More →
avatar for Kevin Cook

Kevin Cook

VP Supply Chain, North America, Sandoz
Kevin Cook serves as Vice President, Supply Chain, North America at Sandoz Inc. where he is also a member of the Sandoz US Executive Committee. With over 25 years in the life sciences industry, Kevin oversees supply for the US and Canadian generics market, including fulfillment to... Read More →
avatar for Alessandro Maselli

Alessandro Maselli

President and Chief Operating Officer, Catalent
Alessandro Maselli was appointed Catalent’s President and Chief Operating Officer in February 2019.  Mr. Maselli joined Catalent in 2010 as Director of Operations at Catalent’s pharmaceutical, nutritional and cosmetics plant in Aprilia, Italy. In 2013, he was appointed General... Read More →
avatar for Holger Weintritt, Ph.D.

Holger Weintritt, Ph.D.

Head of Product Supply, Bayer Pharmaceuticals
Holger has more than 20 years of industry experience in operations and supply chain. At the beginning of his career, he was a Laboratory Manager, Plant Manager, and Chief of Staff. Afterwards, he held various positions in the Supply Chain Organization of Bayer’s Crop Science business... Read More →

Tuesday January 18, 2022 1:00pm - 2:00pm EST

3:50pm EST

The next mRNA wave
Biotechs had been laboring for years on mRNA drug research, but the work took a major leap forward with the approval of the Moderna and Pfizer/BioNTech COVID-19 vaccines. Their success has revved up mRNA programs at more than a dozen companies working on mRNA vaccines and treatments for a range of diseases from flu to cystic fibrosis. The market opportunity is huge, and Big Pharma is hungry for promising companies to snap up or make licensing deals with. We’ll look at the new landscape. 

avatar for Annalee Armstrong

Annalee Armstrong

Senior Editor, Fierce Biotech
Annalee Armstrong is a senior editor for Fierce Biotech. Prior to joining Fierce in April 2021, Annalee was an associate editor for S&P Global Market Intelligence’s healthcare news team. Before that, she was the EPA reporter covering climate and energy policy on the Hill in Washington... Read More →

avatar for Camille Bedrosian

Camille Bedrosian

Chief Medical Officer, Ultragenyx Pharmaceutical Inc.
Dr. Bedrosian joined Ultragenyx in January 2018 as Chief Medical Officer and Executive Vice President. In this role, she provides strategic leadership to the clinical development and translational research programs, and oversees global development functions including: Medical, Clinical... Read More →
avatar for Geoffrey von Maltzahn

Geoffrey von Maltzahn

Co-Founder, CEO, Board Director, Tessera Therapeutics
Geoffrey von Maltzahn is co-Founder, chief executive officer, and board director of Tessera Therapeutics, as well as a general partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental... Read More →
avatar for Jean-Francois Toussaint

Jean-Francois Toussaint

Head of Research and Development, Sanofi Pasteur
Jean-François is the global head of R&D for Sanofi Pasteur since February 2021. He obtained a PhD in bioengineering and animal sciences from the University of Gembloux in Belgium. He spent the next 4 years of his career on diagnostic at the Belgian reference center for animal diseases... Read More →

Tuesday January 18, 2022 3:50pm - 4:35pm EST
Wednesday, January 19

9:30am EST

Collaboration 2022 Style
In 2020, the pandemic spurred drugmakers to band together to find solutions. Vaccine rivals teamed up on development, a consortium of players pooled resources for plasma research, Big Pharma teamed to scale up manufacturing and more. Executives across the industry talked about extending that cooperative spirit beyond the pandemic. What’s the state of collaboration in biopharma now? We’ll explore the latest cooperative efforts tackling the pandemic and other common problems the industry wants to solve.  

avatar for Eric Sagonowsky

Eric Sagonowsky

Senior Editor, Fierce Pharma
Eric Sagonowsky is an editor with the FierceMarkets Life Sciences team. Before joining Fierce in November 2014, Eric worked as a news reporter for the Manistee News Advocate in Manistee, Mich., covering government and crime issues. Eric graduated from Ohio University's E.W. Scripps... Read More →

avatar for Philippe Alen, Ph.D.

Philippe Alen, Ph.D.

Vice President and Head of Business Development, Licensing and Alliance Management for Cardiovascular Diseases, Bayer Pharmaceuticals
Philippe Alen, PhD, is Vice President and Head of Business Development, Licensing and Alliance Management for Cardiovascular Diseases at Bayer Pharmaceuticals. He has over 20 years of experience across biopharma R&D, global marketing and business development.At Bayer, Dr. Alen is... Read More →
avatar for Alban De-La-Sabliere

Alban De-La-Sabliere

Head of Sanofi Partnering, Sanofi
​Alban De-La-Sabliere is Head of Sanofi Partnering, in charge of Sanofi Ventures, Business Development & Licensing, Alliance Management and Competitive Intelligence. The Sanofi Partnering team is a major contributor in making Sanofi’s pipeline one of the best and most exciting... Read More →
avatar for Angus Grant

Angus Grant

Chief Business Officer, BeiGene
Angus Grant, Ph.D. joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In... Read More →
avatar for Cristin Hubbard

Cristin Hubbard

Global Head of Diagnostics Partnering, Roche
Cristin Hubbard is responsible for bringing external innovation into the Roche Diagnostics Group. In her role as Global Head of Diagnostics Partnering, Cristin is a member of the Diagnostics Leadership Team based at Roche’s Headquarters in Basel.  Having grown up in California... Read More →
avatar for Martin Meeson

Martin Meeson

CEO, FUJIFILM Diosynth Biotechnologies
Martin Meeson is a seasoned executive who brings extensive global experience to the Biotech and Pharmaceutical markets.Martin was named Chief Executive Officer on April 1st, 2020, after serving as Chief Operating Officer and President of our US FDB operations (North Carolina and Texas... Read More →

Wednesday January 19, 2022 9:30am - 10:15am EST

1:00pm EST

The future is bright for women's health
Even though women control 80% of the healthcare spend in the United States, the system often leaves them frustrated with a fragmented healthcare experience. However, innovative companies are offering new models of care that deliver an integrated experience to women over their entire life, with a focus on prevention. In this discussion, leaders from women's health startups Tia and Hers (from Hims & Hers) as well as a female healthcare investor will explain why healthcare works better for everyone when it works for women, why women's health has become a hot market for investment and what the future of women's health will look like. Panelists also will discuss how traditional providers can work both within and outside of their four walls to grow their influence with the most powerful healthcare consumer.

avatar for Heather Landi

Heather Landi

Senior Editor, Fierce Healthcare
Heather Landi is a senior editor at Fierce Healthcare, overseeing the team's coverage of health IT and digital health news and trends across the country. She has covered the healthcare technology market for several years in the business-to-business media space.In her recent work... Read More →

avatar for Lynne Chou O'Keefe

Lynne Chou O'Keefe

Founder and Managing Partner, Define Ventures
Lynne Chou O’Keefe is the Founder and Managing Partner of Define Ventures, an early stage venture capital firm focused on investing in digital health companies redefining healthcare. Define Ventures focuses on incubation, seed, Series A, and Series B stage digital health startups... Read More →
avatar for Carolyn Witte

Carolyn Witte

Co-Founder & CEO, Tia
Carolyn Witte, CEO and Co-Founder of Tia, views it as her mission in life to fight healthcare inequalities women face. After experiencing her own set of health struggles and seeing how the healthcare system is not built for women, Carolyn started Tia to reimagine women’s healthcare from the ground up. Together with he... Read More →
avatar for Hilary Coles

Hilary Coles

Co-founder & SVP Brand & Innovation, hims & hers
Hilary Coles is co-founder and SVP of Brand & Innovation at Hims & Hers, a multi-specialty telehealth company that connects customers to licensed healthcare professionals, enabling them to access high quality medical care for numerous conditions related to primary care, mental health... Read More →

Wednesday January 19, 2022 1:00pm - 2:00pm EST
Thursday, January 20

9:30am EST

As virtual-first plans proliferate, are they here to stay?
Multiple major payers have launched plans that put virtual care front and center, or are at the very least significantly expanding their virtual care options in the wake of COVID-19. But are these plans really here for the long haul? What does it take to balance a virtual care focus with access to in-person care? Hear from industry experts about what’s next for these plans.

avatar for Paige Minemyer

Paige Minemyer

Senior Editor, Fierce Health Payer
Paige Minemyer is a senior editor at Fierce Healthcare, overseeing the team’s coverage of payer trends and news from across the country. Since joining the Fierce team, she’s covered the spectrum of the healthcare industry, including providers, technology and policy, and prior... Read More →

avatar for Kelly Bliss

Kelly Bliss

President of US Group Health, Teladoc Health
Kelly Bliss is President of U.S. Group Health. She oversees sales, client management, client and commercial operations for the business.Ms. Bliss has strong expertise in creating cohesive client-focused organizations. Most recently, she held the position of chief client officer at... Read More →
avatar for Jill Dailey

Jill Dailey

Vice President, Commercial Product & Strategic Programs, Aetna
As VP of Aetna Commercial Product & Strategic Programs, Jill is responsible for commercial product strategy and portfolio management, new product development, and delivery excellence. She leads a team that builds products and solutions to meet the needs of all sizes of employers as... Read More →
avatar for Shawna Dodds

Shawna Dodds

Vice President of Product Development, Cigna
Shawna has over 20 years of product experience in the health plan industry.  She currently is a Managing Director of Product at Cigna, responsible for all US Commercial Medical solutions.  Prior to this role, she led strategy work for high priority conditions such as Diabetes and... Read More →
avatar for Carrie Kincaid

Carrie Kincaid

Vice President, Individual Markets, Priority Health
Carrie Kincaid is Vice President, Individual Markets at Priority Health. In this role she leads the company’s portfolio of individual products, including strategy, product and market development, risk adjustment, sales and operations. Previously, she led risk adjustment work across... Read More →

Thursday January 20, 2022 9:30am - 10:30am EST

1:00pm EST

Digital first launches - The new post-COVID landscape
As a result of the pandemic, many pharma and biotech companies could not launch products in the same manner as they had done previously with face-to-face interactions with HCPS.  Companies needed to adapt and launch their products completely digitally which created unique challenges but also new opportunities for the future.  We will look at what worked, what didn’t and discuss strategies for these types of launches going forward.

avatar for Stephanie Butler

Stephanie Butler

Senior Conference Director, Fierce Life Sciences
Stephanie Butler is a Senior Conference Production Director with Fierce Life Sciences.  Previously, Ms. Butler was a Division Manager at the American Conference Institute where she was responsible for the for the creation and development of legal and business conferences in the Pharmaceutical/Life... Read More →

avatar for Gina Chapman

Gina Chapman

Senior Vice President, OMNI Business Unit Head, Genentech
As Senior Vice President, OMNI Business Unit Head at Genentech, Gina leads a team of ~260 people, including Marketing teams, who report directly into therapeutic area Squad Leads. Access, Medical and Field partners are a part of the Business Unit network. The OMNI Business Unit is... Read More →
avatar for Robert La Caze

Robert La Caze

Member of the Executive Committee of Bayer's Pharmaceutical Division and Head of the Oncology SBU,, Bayer Pharmaceuticals
Robert LaCaze is an accomplished and recognized oncology leader with focus on driving innovation and value for patients. Robert’s success is driven by his passion for Oncology and 30 years of bio-pharmaceutical experience mainly in specialty areas like Oncology. Currently as the... Read More →
avatar for David Libby

David Libby

SVP, Region Head North America, Ultragenyx
David is currently Senior Vice President, North America Region for Ultragenyx a leading biotechnology company focused on finding breakthrough treatments for rare diseases leveraging multiple modalities including gene therapies, mRNA, and recombinant DNA biologic treatments. David... Read More →
avatar for Lars Merk

Lars Merk

Sr. Director Global Commercial Digital & Innovation, AstraZeneca
Lars Merk is the Global Director of Omnichannel Strategy for Astra Zeneca. He is known for driving innovation and business results by maintaining both marketing discipline and customer focus in his roles over the years. Lars has consistently been recognized by the industry as an innovative... Read More →

Thursday January 20, 2022 1:00pm - 2:00pm EST